JP7320611B2 - 新規鉄組成物及びその製造方法と使用方法 - Google Patents

新規鉄組成物及びその製造方法と使用方法 Download PDF

Info

Publication number
JP7320611B2
JP7320611B2 JP2021550178A JP2021550178A JP7320611B2 JP 7320611 B2 JP7320611 B2 JP 7320611B2 JP 2021550178 A JP2021550178 A JP 2021550178A JP 2021550178 A JP2021550178 A JP 2021550178A JP 7320611 B2 JP7320611 B2 JP 7320611B2
Authority
JP
Japan
Prior art keywords
iron
samples
molecular weight
sucrose
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021550178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522009A (ja
JP2022522009A5 (enExample
Inventor
カイザー，ドナルド・ジェフリー
ギエム，アルバロ・エフ
ゼーガー，リチャード・エイ
Original Assignee
レニバス・セラピューティクス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レニバス・セラピューティクス・インコーポレイテッド filed Critical レニバス・セラピューティクス・インコーポレイテッド
Publication of JP2022522009A publication Critical patent/JP2022522009A/ja
Publication of JP2022522009A5 publication Critical patent/JP2022522009A5/ja
Priority to JP2023118851A priority Critical patent/JP7646750B2/ja
Application granted granted Critical
Publication of JP7320611B2 publication Critical patent/JP7320611B2/ja
Priority to JP2025033475A priority patent/JP2025084949A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021550178A 2019-02-28 2020-02-28 新規鉄組成物及びその製造方法と使用方法 Active JP7320611B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023118851A JP7646750B2 (ja) 2019-02-28 2023-07-21 新規鉄組成物及びその製造方法と使用方法
JP2025033475A JP2025084949A (ja) 2019-02-28 2025-03-04 新規鉄組成物及びその製造方法と使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962812028P 2019-02-28 2019-02-28
US62/812,028 2019-02-28
PCT/US2020/020517 WO2020176894A1 (en) 2019-02-28 2020-02-28 Novel iron compositions and methods of making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023118851A Division JP7646750B2 (ja) 2019-02-28 2023-07-21 新規鉄組成物及びその製造方法と使用方法

Publications (3)

Publication Number Publication Date
JP2022522009A JP2022522009A (ja) 2022-04-13
JP2022522009A5 JP2022522009A5 (enExample) 2022-10-05
JP7320611B2 true JP7320611B2 (ja) 2023-08-03

Family

ID=70190086

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021550178A Active JP7320611B2 (ja) 2019-02-28 2020-02-28 新規鉄組成物及びその製造方法と使用方法
JP2023118851A Active JP7646750B2 (ja) 2019-02-28 2023-07-21 新規鉄組成物及びその製造方法と使用方法
JP2025033475A Pending JP2025084949A (ja) 2019-02-28 2025-03-04 新規鉄組成物及びその製造方法と使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023118851A Active JP7646750B2 (ja) 2019-02-28 2023-07-21 新規鉄組成物及びその製造方法と使用方法
JP2025033475A Pending JP2025084949A (ja) 2019-02-28 2025-03-04 新規鉄組成物及びその製造方法と使用方法

Country Status (20)

Country Link
US (4) US11292813B2 (enExample)
EP (2) EP3930686B1 (enExample)
JP (3) JP7320611B2 (enExample)
KR (1) KR102997223B1 (enExample)
CN (2) CN113825496B (enExample)
AU (2) AU2020229381A1 (enExample)
CA (1) CA3131596A1 (enExample)
DK (1) DK3930686T3 (enExample)
ES (1) ES2955019T3 (enExample)
FI (1) FI3930686T3 (enExample)
HR (1) HRP20230989T1 (enExample)
HU (1) HUE063182T2 (enExample)
LT (1) LT3930686T (enExample)
PL (1) PL3930686T3 (enExample)
PT (1) PT3930686T (enExample)
RS (1) RS64652B1 (enExample)
SG (1) SG11202109323UA (enExample)
SI (1) SI3930686T1 (enExample)
SM (1) SMT202300276T1 (enExample)
WO (1) WO2020176894A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022056378A1 (en) * 2020-09-11 2022-03-17 Renibus Therapeutics, Inc. Method for treating cancer with kidney protection
JP2024534172A (ja) * 2021-08-27 2024-09-18 ヴァイフォー（インターナショナル）アーゲー 鉄組成物並びにそれらを作製及び使用する方法
WO2024069644A1 (en) * 2022-09-30 2024-04-04 West Bengal Chemical Industries Limited A pharmaceutically acceptable ferric carboxymaltose and preparation thereof
CN115969714B (zh) * 2022-11-03 2025-03-11 华熙生物科技股份有限公司 具有光谱选择性的防晒组合物及其应用
EP4772557A1 (en) 2023-08-29 2026-07-08 Daicel Corporation Curable epoxy composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103340827A (zh) 2013-07-16 2013-10-09 成都天台山制药有限公司 蔗糖铁注射液及其制法
CN104558064A (zh) 2013-10-29 2015-04-29 北京京卫信康医药科技发展有限公司 蔗糖铁的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE862482C (de) * 1950-05-14 1953-01-12 Merck Chem Fab E Verfahren zur Darstellung haltbarer, injizierbarer Loesungen von Salzen des dreiwertigen Eisens
US5624668A (en) 1995-09-29 1997-04-29 Luitpold Pharmaceuticals, Inc. Iron dextran formulations
DE19547356A1 (de) 1995-12-19 1997-06-26 Vifor Int Ag Adsorbens für Phosphat aus wäßrigem Medium, dessen Herstellung und Verwendung
US20030232738A1 (en) * 1998-04-20 2003-12-18 National Jewish Medical And Research Center Method and composition for increasing CD4+ T lymphocyte immune responsiveness
CA2365787C (en) * 2000-12-20 2006-02-14 Dialysis Solutions Inc. Sterile low bicarbonate dialysis concentrate solutions
DE60229303D1 (de) * 2002-08-26 2008-11-20 Vifor Int Ag Bioäquivalenztest für eisenhaltige formulierungen
WO2005094202A2 (en) * 2004-03-16 2005-10-13 Navinta, Llc Iron sucrose complexes and method of manufacture thereof
WO2006061685A1 (en) 2004-12-06 2006-06-15 Emcure Pharmaceuticals Limited A cost-effective process for preparation of manufacture of iron sucrose
ITMO20050056A1 (it) 2005-03-15 2006-09-16 Biofer Spa Processo per la preparazione di complessi del ferro trivalente con zuccheri mono-, di- e polisaccaridi.
CN100528237C (zh) 2005-04-26 2009-08-19 重庆医药工业研究院有限责任公司 多核的氢氧化铁-糖复合物的制备方法
EP1757299A1 (de) * 2005-08-25 2007-02-28 Vifor (International) Ag Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung
EP2992886A1 (en) 2006-10-04 2016-03-09 InfaCare Pharmaceutical Corporation High-purity large-scale preparation of stannsoporfin
EP1947120A1 (de) 2007-01-19 2008-07-23 Vifor (International) Ag Eisen-Kohlenhydrat-Komplex-Verbindungen
IN269965B (enExample) 2007-06-25 2015-11-27 Claris Lifescienses Ltd
TWI592159B (zh) 2007-11-16 2017-07-21 威佛（國際）股份有限公司 藥學組成物
CN102341111A (zh) 2009-03-02 2012-02-01 维福（国际）股份公司 磷酸盐吸附剂
CN106176808A (zh) * 2010-10-19 2016-12-07 长春纳米生技公司 金属离子纳米簇组合物
EP2548562A1 (de) 2011-07-18 2013-01-23 SeBo GmbH Kombinationstherapie mit Eisen-basierenden Phosphatadsorbern
EP2647389A1 (en) * 2012-04-04 2013-10-09 Charité - Universitätsmedizin Berlin Magnetic nanoparticle dispersion, its preparation and diagnostic and therapeutic use
IN2013CH05383A (enExample) 2013-11-21 2015-08-28 Reddy’S Lab Ltd Dr
CN104098616B (zh) 2014-05-27 2016-04-20 广西壮族自治区化工研究院 一种蔗糖铁的制备方法
AU2015324103C1 (en) * 2014-09-29 2020-08-20 Fred Hutchinson Cancer Center Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
US20190106454A1 (en) * 2016-03-23 2019-04-11 Fred Hutchinson Cancer Research Center Compounds linked with a saccharide metal complex and uses thereof
WO2018148217A1 (en) * 2017-02-08 2018-08-16 Fred Hutchinson Cancer Research Center Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
SG11202001594TA (en) 2017-09-11 2020-03-30 Pharmacosmos Holding As Iron complex compounds for therapeutic use
CN109912675B (zh) 2017-12-13 2020-09-15 北京市林业果树科学研究院 一种蔗糖亚铁及其制备方法
CN110063965A (zh) 2019-06-04 2019-07-30 吉林省富生医疗器械有限公司 一种血液透析浓缩物
CN112315902B (zh) 2019-08-05 2022-05-13 南京恒生制药有限公司 一种低易变铁含量蔗糖铁注射液制备方法
WO2022072439A1 (en) 2020-09-29 2022-04-07 Lg Bionano Co. Ltd Methods of preparing iron complexes
CN112168844A (zh) 2020-09-29 2021-01-05 神奈纳米医药技术(珠海)有限公司 一种氢氧化铁碳水化合物复合物的制备方法
CN112156109A (zh) 2020-09-29 2021-01-01 神奈纳米医药技术(珠海)有限公司 氢氧化铁-糖络合物的制备方法及其应用
CN115531414A (zh) 2021-06-30 2022-12-30 南京恒生制药有限公司 一种新型蔗糖铁复合物及其制备方法
JP2024534172A (ja) 2021-08-27 2024-09-18 ヴァイフォー（インターナショナル）アーゲー 鉄組成物並びにそれらを作製及び使用する方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103340827A (zh) 2013-07-16 2013-10-09 成都天台山制药有限公司 蔗糖铁注射液及其制法
CN104558064A (zh) 2013-10-29 2015-04-29 北京京卫信康医药科技发展有限公司 蔗糖铁的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kidney Int.，2016年，Vol.90，pp.67-76

Also Published As

Publication number Publication date
HRP20230989T1 (hr) 2023-12-08
HUE063182T2 (hu) 2024-01-28
US11834471B2 (en) 2023-12-05
EP4234020A3 (en) 2023-10-04
US20230070012A1 (en) 2023-03-09
EP4234020A2 (en) 2023-08-30
WO2020176894A1 (en) 2020-09-03
PT3930686T (pt) 2023-09-04
JP2025084949A (ja) 2025-06-03
KR102997223B1 (ko) 2026-07-29
CN119488480A (zh) 2025-02-21
DK3930686T3 (da) 2023-09-11
US20240002427A1 (en) 2024-01-04
SI3930686T1 (sl) 2023-11-30
LT3930686T (lt) 2023-10-10
PL3930686T3 (pl) 2023-11-27
US11292813B2 (en) 2022-04-05
CN113825496A (zh) 2021-12-21
EP3930686B1 (en) 2023-05-31
US20220242901A1 (en) 2022-08-04
SMT202300276T1 (it) 2023-11-13
FI3930686T3 (fi) 2023-09-01
EP3930686A1 (en) 2022-01-05
CN113825496B (zh) 2024-09-27
JP2023139154A (ja) 2023-10-03
AU2020229381A1 (en) 2021-09-16
KR20210133243A (ko) 2021-11-05
JP2022522009A (ja) 2022-04-13
RS64652B1 (sr) 2023-10-31
AU2025230678A1 (en) 2025-10-02
US11840552B2 (en) 2023-12-12
SG11202109323UA (en) 2021-09-29
US20200277325A1 (en) 2020-09-03
CA3131596A1 (en) 2020-09-03
ES2955019T3 (es) 2023-11-28
JP7646750B2 (ja) 2025-03-17

Similar Documents

Publication Publication Date Title
JP7646750B2 (ja) 新規鉄組成物及びその製造方法と使用方法
Himmelstoß et al. Long‐term colloidal and chemical stability in aqueous media of NaYF4‐type upconversion nanoparticles modified by ligand‐exchange
Jahn et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a new intravenous iron preparation and its clinical implications
US6773924B2 (en) Method for producing purified hematinic iron-saccharidic complex and product produced
Alanazi et al. Selective and reliable fluorometric quantitation of anti-cancer drug in real plasma samples using nitrogen-doped carbon dots after MMIPs solid phase microextraction: Monitoring methotrexate plasma level
Stinnett et al. 2D gadolinium oxide nanoplates as T1 magnetic resonance imaging contrast agents
Fülöp et al. Study on the dissolution improvement of albendazole using reconstitutable dry nanosuspension formulation
Cappellari et al. Synthesis of ultra-small cysteine-capped gold nanoparticles by pH switching of the Au (I)–cysteine polymer
HK40066204A (en) Novel iron compositions and methods of making and using the same
HK40066204B (en) Novel iron compositions and methods of making and using the same
HK40098133A (en) Novel iron compositions and methods of making and using the same
HK40066891B (en) Novel iron compositions and methods of making and using the same
HK40066891A (en) Novel iron compositions and methods of making and using the same
Uchman et al. Micelle-like nanoparticles of block copolymer poly (ethylene oxide)-block-poly (methacrylic acid) incorporating fluorescently substituted metallacarboranes designed as HIV protease inhibitor interaction probes
Takai et al. Synthesis and characterization of boron-containing biocompatible polymer-coated Gd2O3 nanoparticles for neutron capture therapy-based theranostics
Lebedev et al. Biocompatible water-soluble endometallofullerenes: peculiarities of self-assembly in aqueous solutions and ordering under an applied magnetic field
Shulenina et al. A structural study of biocompatible magnetic nanofluid with synchrotron radiation-based X-ray scattering techniques
Noori et al. Spectrophotometric Determination of Bromhexine-HCl by Using Prepared Silver Nanoparticles
Grossman et al. Preclinical Efficacy and Toxicity Testing of Engineered
EP1719495A2 (en) Method for producing purified hematinic iron-saccharidic complex and product produced
JP7557902B2 (ja) 修飾金属ナノ粒子及び医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220927

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230605

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230627

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230724

R150 Certificate of patent or registration of utility model

Ref document number: 7320611

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250